http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103989693-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 |
| filingDate | 2014-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103989693-B |
| titleOfInvention | Application of scutelloside in preparation of acute hemolytic uremic syndrome treatment drugs |
| abstract | The invention provides an application of scutelloside in the preparation of acute hemolytic uremic syndrome treatment drugs. Hela cell protection test and mouse acute hemolytic uremic syndrome models confirm that scutelloside has a good treatment effect on the acute hemolytic uremic syndrome, especially the acute hemolytic uremic syndrome caused by Escherichia coli II Shiga toxins. Compared with antibiotics, scutelloside has the advantages of no drug resistance and high curate rate in the treatment of the acute hemolytic uremic syndrome. |
| priorityDate | 2013-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.